Drug Trial Radar · NCT07215273
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 13, 2026
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Elion Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if EL219 is safe and effective compared to liposomal amphotericin B (LAmB) or voricanozole for early treatment of invasive mould infections
Conditions
- Invasive Mould Infection
Interventions
EL219Drug
EL219 is specifically being developed for early antifungal therapy (EAT), when infection is suspected due to highly suggestive signs and symptoms of disease; in high-risk people, antifungals are recommended even before confirmation of the microbial cause of infection, because delayed therapy is associated with poor outcomes in those who lack adequate immune responses. EL219 may provide a once-weekly alternative to LAmB and other polyenes that could also reduce the toxicities that often limit the frequency and duration of administration for these highly efficacious antifungals.
Active Comparator- IV Antifungal (LAmB or voriconazole)Drug
LAmB has broad-spectrum activity but its use is limited by toxicity and once-daily IV administration. It is not administered outside of the monitored setting given risks for electrolyte disturbances and cardiac arrhythmias. Voriconazole is a first-line therapy for IA and the most common azole used in the US and globally but does not have activity against many non-Aspergillus moulds.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Outcome/Measure All-Cause MortalityTime frame: From enrollment to Day 21
- Primary Outcome/Measure SAE TEAETime frame: From enrollment to the end of treatment at Day 42
Locations
30 sites in 6 countries. Site status is shown where the registry gives one.
U. of Alabama at Birmingham
Birmingham, Alabama · Recruiting
UC Davis Medical Center
Sacramento, California · Recruiting
Augusta University Medical Center
Augusta, Georgia · Recruiting
John Hopkins University
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
U. of Michigan
Ann Arbor, Michigan · Recruiting
Washington U.
St Louis, Missouri · Recruiting
U. of Texas, MD Anderson
Houston, Texas · Recruiting
U. of Texas Health Sciences Center at San Antonio
San Antonio, Texas · Recruiting
U. of Washington
Seattle, Washington · Recruiting
AZ Sint-Jan Brugge
Bruges, Belgium · Recruiting
Universite Libre de Bruxelles (ULB) - Institut Jules Bordet
Brussels, Belgium · Recruiting
UZ Gent
Ghent, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Centre Hospitalier Universitaire (CHU) de Liege
Liège, Belgium · Recruiting
Vancouver General Hospital
Vancouver, British Columbia, Canada · Recruiting
Juravinski Hospital
Hamilton, Ontario, Canada · Recruiting
University Health Network (UHN) - Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Centre Hospitalier d'Argenteuil
Argenteuil, France · Recruiting
AP-HP Hopital Henri Modor
Créteil, France · Recruiting
AP-HP Hopital Saint-Louis
Paris, France · Recruiting
Istituto Europeo di Oncologia
Milan, Italy · Recruiting
Fondazione Policlinico Universitario A. Gemelli IRCCS- Universita Cattolica del Sacro Cuore
Roma, Italy · Recruiting
Hospital del Mar
Barcelona, Spain · Recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Clinic Barcelona
Barcelona, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Universitario Puerta de Hierro
Majadahonda, Spain · Recruiting
Hospital Clinico Universitario de Salamanca
Salamanca, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.